Targeted
Cure Tec
Shaping the Future of
Targeted Treatment
WHAT DRIVES US
Our purpose is to save lives and to restore the quality of life.
We develop technologies that deliver therapeutics directly to affected organs – precisely where they’re needed most.
Maximizing efficacy. Reducing side effects. Minimally invasive.
OUR FIRST APPLICATION
Addressing an unmet need to improve patient outcomes.
An Aneurysmal subarachnoid hemorrhage (aSAH) is an acute brain bleed caused by the rupture of a cerebral aneurysm – often in previously healthy individuals.
In the critical phase delayed cerebral ischemia can drastically reduce blood flow to the brain, often resulting in severe neurological deficits or death.
Current treatment options are limited: Systemically administered drugs are often ineffective or cannot be used safely due to significant side effects.
54
patients average age
600 K
patients per year
50 %
patients with inadequate care
OUR SOLUTION
Targeted therapy – minimally invasive, precisely controlled, locally effective
Targeted Cure Tec is developing a novel medical device technology combined with an innovative formulation of pharmacological agents.
Through a minimally invasive endovascular catheter approach, the therapeutic agent is precisely delivered to the site of disease, crossing the blood-brain barrier and enabling controlled, sustained drug release as long as needed.
OUR COMPETENCE
Science translated into healing.
Born from clinical experience – advanced through research and technology. A team with more than 25 years of expertise in translational medicine and biosciences, complemented by strong process know-how, operational excellence, and entrepreneurial vision. Built on international reputation, global experience, and a network that connects research, clinical practice and industry.
Prof. Dr. Daniel Hänggi
CEO, Founder
One of the leading international experts in the field of vascular neurosurgery. The Director of Translational Neurosurgery at INI Hannover has performed over 10,000 operations and written more than 300 scientific publications.
Robert Schovenberg
CBO, Co-Founder
Entrepreneurial expertise from a serial founder and investor with a track record in building and scaling tech companies.
Dr. Christian Aichinger
COO, Co-Founder
Pharmaceutical market launch expertise from a manager with decades of experience in the development, launch and execution of therapies and medical devices in leading global companies.
Toru Takama
CEO TCT Japan
Dr. Dirk Besse
Chairman of the Advisory Board
Dr. Dirk Besse is Managing Partner of the German office of Morrison Foerster and leads its European M&A practice. He specializes in cross-border transactions and capital markets law, focusing on pharma, finance, software, and high-tech. He has published widely and served on supervisory boards.
Dr. Timm Hassemer
Senior Project Manager
Cara Ludermann
Founders Associate
Daniela Mahan
Head of Quality & Regulatory Affairs
Miyuki Matsumoto
Founders Associate
Dr. Giulia Moscatiello
Manager Scientific Affairs
Yu Nakanishi
Founders Associate TCT Japan
Sunita Sur Roy
Head of Finance
Julia Wolfrat
Consultant Quality Management
Nils Beyer
Expert Advisor in Regulatory Affairs
Steffen Gerbus
Expert Advisor in Taxation
Together for improving therapies – driven by science, defined by impact.
POTENTIAL & OPPORTUNITIES
Science-to-Solution Pipeline: One Technology – Multiple Applications
The technology developed by Targeted Cure Tec offers a broad spectrum of potential applications beyond neurology, opening perspectives for cross-organ treatments and next-generation targeted therapies.
We aim to unlock this potential through collaboration and shared purpose – shaping the future of targeted treatment together.
